Eljack, S.;                     Allard-Vannier, E.;                     Misericordia, Y.;                     Hervé-Aubert, K.;                     Aubrey, N.;                     Chourpa, I.;                     Faggad, A.;                     David, S.    
        Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells. Pharmaceutics 2022, 14, 2537.
    https://doi.org/10.3390/pharmaceutics14112537
    AMA Style
    
                                Eljack S,                                 Allard-Vannier E,                                 Misericordia Y,                                 Hervé-Aubert K,                                 Aubrey N,                                 Chourpa I,                                 Faggad A,                                 David S.        
                Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells. Pharmaceutics. 2022; 14(11):2537.
        https://doi.org/10.3390/pharmaceutics14112537
    
    Chicago/Turabian Style
    
                                Eljack, Sahar,                                 Emilie Allard-Vannier,                                 Yoann Misericordia,                                 Katel Hervé-Aubert,                                 Nicolas Aubrey,                                 Igor Chourpa,                                 Areeg Faggad,                                 and Stephanie David.        
                2022. "Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells" Pharmaceutics 14, no. 11: 2537.
        https://doi.org/10.3390/pharmaceutics14112537
    
    APA Style
    
                                Eljack, S.,                                 Allard-Vannier, E.,                                 Misericordia, Y.,                                 Hervé-Aubert, K.,                                 Aubrey, N.,                                 Chourpa, I.,                                 Faggad, A.,                                 & David, S.        
        
        (2022). Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells. Pharmaceutics, 14(11), 2537.
        https://doi.org/10.3390/pharmaceutics14112537